 |
|
Hospice Use Among Medicare Managed Care and Fee-for-Service Patients Dying With Cancer
Ellen P. McCarthy, PhD, MPH;
Risa B. Burns, MD, MPH;
Quyen Ngo-Metzger, MD, MPH;
Roger B. Davis, ScD;
Russell S. Phillips, MD
JAMA. 2003;289:2238-2245.
Context For most patients aged 65 years or older with cancer, hospice services are uniformly covered by Medicare. Hospice care is believed to improve care for patients at the end of life. However, few patients use hospice and others enroll too late to maximize the benefits of hospice services.
Objectives Because type of insurance may affect use, we examined whether patients with Medicare managed care insurance enrolled in hospice earlier and had longer hospice stays than patients with Medicare fee-for-service (FFS) insurance.
Design and Setting Retrospective analysis of the last year of life using the Linked Medicare-Tumor Registry Database in 1 of 9 Surveillance, Epidemiology, and End Results program coverage areas.
Patients A total of 260 090 Medicare beneficiaries aged 66 years or older diagnosed with first primary lung (n = 62 117), colorectal (n = 57 260), prostate (n = 59 826), female breast (n = 37 609), bladder (n = 19 598), pancreatic (n = 11 378), gastric (n = 9599), or liver (n = 2703) cancer between January 1, 1973, and December 31, 1996, and who died between January 1, 1988, and December 31, 1998.
Main Outcome Measures Time from diagnosis to hospice entry and hospice length of stay for patients enrolled in FFS vs managed care plans after adjusting for patient demographics, tumor registry, year of hospice entry, and type and cancer stage.
Results Of the 260 090 patients, most were men (59%), white (85%), and enrolled in FFS (89.7%). Only 54 937 patients (21.1%) received hospice care before death. Hospice use varied by type of primary cancer ranging from 31.8% of patients with pancreatic cancer to 15.6% with bladder cancer. Managed care patients were more likely to use hospice than FFS patients (32.4% vs 19.8%, P<.001). Among hospice patients, median (interquartile range) length of stay was longer for managed care vs FFS patients (32 days [11-82] vs 25 days [9-66], P<.001). After adjustment, managed care patients had higher rates of hospice enrollment (adjusted hazard ratio [HR], 1.38; 95% CI, 1.35-1.42) and had a longer length of stay (adjusted HR, 0.91; 95% CI, 0.88-0.94) vs FFS patients. Managed care patients were less likely to enroll in hospice within 7 days of their death (18.6% vs 22.6%, P<.001) and somewhat more likely to enroll in hospice more than 180 days before death (7.8% vs 6.1%, P<.001); the results for each of the 8 cancer diagnoses were similar. Hospice enrollment and length of stay among managed care vs FFS patients differed significantly by region.
Conclusion Medicare beneficiaries enrolled in managed care had consistently higher rates of hospice use and significantly longer hospice stays than those enrolled in FFS. Although these differences may reflect patient and family preferences, our findings raise the possibility that some managed care plans are more successful at facilitating or encouraging hospice use for patients dying with cancer.
Author Affiliations: Department of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Mass.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTER
Hospice Use in Medicare Beneficiaries With Cancer
Bruno Gagnon
JAMA. 2003;290(12):1578.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Length of Survival in Hospice for Cancer Patients Referred From a Comprehensive Cancer Center
Younis et al.
AM J HOSP PALLIAT CARE 2009;26:281-287.
ABSTRACT
Discussions With Physicians About Hospice Among Patients With Metastatic Lung Cancer
Huskamp et al.
Arch Intern Med 2009;169:954-962.
ABSTRACT
| FULL TEXT
Racial and Ethnic Differences in End-of-Life Costs: Why Do Minorities Cost More Than Whites?
Hanchate et al.
Arch Intern Med 2009;169:493-501.
ABSTRACT
| FULL TEXT
What Are Terminally Ill Cancer Patients Told About Their Expected Deaths? A Study of Cancer Physicians' Self-Reports of Prognosis Disclosure
Daugherty and Hlubocky
JCO 2008;26:5988-5993.
ABSTRACT
| FULL TEXT
Comparison of Prospective and Retrospective Indicators of the Quality of End-of-Life Cancer Care
Setoguchi et al.
JCO 2008;26:5671-5678.
ABSTRACT
| FULL TEXT
Aggressiveness of Cancer Care Near the End of Life: Is It a Quality-of-Care Issue?
Earle et al.
JCO 2008;26:3860-3866.
ABSTRACT
| FULL TEXT
Racial/Ethnic Disparities in Liver Transplant Surgery and Hospice Use: Parallels, Differences, and Unanswered Questions
Smith et al.
AM J HOSP PALLIAT CARE 2008;25:285-291.
ABSTRACT
A Comprehensive Community-Based Model for Hospice Care
Harrison and Ford
AM J HOSP PALLIAT CARE 2007;24:119-125.
ABSTRACT
Variations in hospice use among cancer patients.
Keating et al.
JNCI J Natl Cancer Inst 2006;98:1053-1059.
ABSTRACT
| FULL TEXT
The Epidemiology of Sepsis in Patients With Malignancy
Danai et al.
Chest 2006;129:1432-1440.
ABSTRACT
| FULL TEXT
Looking Back From Death: The Value of Retrospective Studies of End-of-Life Care
Earle and Ayanian
JCO 2006;24:838-840.
FULL TEXT
Identification in Administrative Databases of Women Dying of Breast Cancer
Gagnon et al.
JCO 2006;24:856-862.
ABSTRACT
| FULL TEXT
Defining Cancer Patients As Being in the Terminal Phase: Who Receives a Formal Diagnosis, and What Are the Effects?
Aabom et al.
JCO 2005;23:7411-7416.
ABSTRACT
| FULL TEXT
Resurrecting Treatment Histories of Dead Patients: A Study Design That Should Be Laid to Rest
Bach et al.
JAMA 2004;292:2765-2770.
ABSTRACT
| FULL TEXT
Trends in the Aggressiveness of Cancer Care Near the End of Life
Earle et al.
JCO 2004;22:315-321.
ABSTRACT
| FULL TEXT
Hospice Use in Medicare Beneficiaries With Cancer
Gagnon
JAMA 2003;290:1578-1578.
FULL TEXT
|
